Managers / Q2 2020 · view latest →
Essex Woodlands Management, Inc.
CIK 0001542339 · 21 WATERWAY AVE, STE 150, THE WOODLANDS, TX, 77380 · 281-364-1555
Summary
Essex Woodlands Management, Inc. reported $204M in U.S.-listed holdings across 8 positions for Q2 2020.
The portfolio is heavily concentrated: Revance Therapeutics alone accounts for 40.0% of reported value.
The book was largely unchanged from Q1 2020.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 78.5% · $160M
- Other · 21.5% · $44M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| VENUS CONCEPT, INC. | ADDED | +5.40M | 12.42M | +$18M | $43M |
| TELATELA BIO, INC. | ADDED | +317.5K | 1.39M | +$10M | $18M |
| REVANCE THERAPEUTICS INC | HELD | +0 | 3.34M | +$32M | $82M |
| EYEPOINT PHARMACEUTICALS INC | HELD | +0 | 41.91M | −$11M | $32M |
| AXGNAXOGEN INC | HELD | +0 | 2.43M | −$3M | $22M |
| MNOVMEDICINOVA INC | HELD | +0 | 1.11M | +$2M | $6M |
| CATALYST BIOSCIENCES INC | HELD | +0 | 78.6K | +$118,000 | $462,000 |
| ENDOLOGIX INC | HELD | +0 | 125.7K | +$12,000 | $101,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | REVANCE THERAPEUTICS INC | COM | 40.04% | $82M | 3.34M |
| 2 | VENUS CONCEPT, INC. | COM | 21.26% | $43M | 12.42M |
| 3 | EYEPOINT PHARMACEUTICALS INC | COM | 15.62% | $32M | 41.91M |
| 4 | AXGNAXOGEN INChistory → | COM | 11.01% | $22M | 2.43M |
| 5 | TELATELA BIO, INC.history → | COM | 8.85% | $18M | 1.39M |
| 6 | MNOVMEDICINOVA INChistory → | COM NEW | 2.94% | $6M | 1.11M |
| 7 | CATALYST BIOSCIENCES INC | COM NEW | 0.23% | $462,000 | 78.6K |
| 8 | ENDOLOGIX INC | COM NEW | 0.05% | $101,000 | 125.7K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $251M | 5 | May 4, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $318M | 6 | Feb 4, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $307M | 6 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $279M | 6 | Aug 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $347M | 6 | May 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $433M | 7 | Feb 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $350M | 7 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $307M | 7 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $345M | 7 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $404M | 7 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $113M | 6 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $132M | 6 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $173M | 7 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $179M | 7 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $242M | 7 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $242M | 9 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $414M | 9 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $445M | 10 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $451M | 9 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $677M | 9 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $640M | 9 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $385M | 8 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $188M | 8 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $204M | 8 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $155M | 8 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $214M | 8 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $161M | 6 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $173M | 6 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $201M | 8 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $251M | 8 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.